Shawn Cross was appointed Chief Financial Officer of Pacira BioSciences in October 2024. Prior to joining Pacira, he was most recently a member of the leadership team at Applied Molecular Transport, Inc. (Nasdaq: AMTI), a biopharmaceutical company committed to developing novel, oral biological therapeutics to treat severe autoimmune, metabolic, and inflammatory diseases. During his time at Applied Molecular Transport, Mr. Cross served as Chief Financial Officer from March 2020 to May 2022; President and Chief Operating Officer from May 2022 to March 2023; and as Chief Executive Officer and a director from March 2023 through the closing of its merger with Cyclo Therapeutics, Inc., (Nasdaq: CYTH) in December 2023. Prior to Applied Molecular Transport, Mr. Cross was an investment banker focused on the biopharmaceutical industry for over 20 years with both domestic and international experience having lived and worked in major financial centers including New York City, London, and San Francisco. He served as a Managing Director of Healthcare Investment Banking at JMP Securities between September 2018 and February 2020 and previously held senior roles at Deutsche Bank Securities and Wells Fargo Securities. He began his investment banking career in the Healthcare Investment Banking Group at Alex. Brown & Sons. Mr. Cross currently serves on the board of directors of Cyclo Therapeutics, and holds a Master of Business Administration degree from Columbia Business School and a Bachelor of Science degree from the University of California, Los Angeles.